person · Reporting owner
OBrien Christopher Flint
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Former Chief Medical Officer | February 05, 2018 | February 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date February 05, 2018 · Filed February 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,223 |
Reported balance
After 2018-02-05 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2018-02-05 · Sale · Disposed 1,500 · Balance 52,223 F1: Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 54,310 |
Reported balance
After 2018-02-05 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2018-02-05 · Sale · Disposed 1,113 · Balance 54,310 F3: Sale of 1,113 shares of common stock issued upon vesting of restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 55,946 |
Reported balance
After 2018-02-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2018-02-06 · Tax withholding · Disposed 1,014 · Balance 55,946 F4: Payment of tax liability by withholding 1,014 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,636) maintained by the Reporting Person. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $81.49 · Expires 2028-02-05 | Direct | 9,250 |
Reported balance
After 2018-02-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-05 · Grant · Acquired 9,250 · Balance 9,250 F5: Represents option of which 1/24th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/24th of the shares underlying the option becomes vested and exercisable each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Sale of 1,113 shares of common stock issued upon vesting of restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F4: Payment of tax liability by withholding 1,014 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,636) maintained by the Reporting Person.
F5: Represents option of which 1/24th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/24th of the shares underlying the option becomes vested and exercisable each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2018 Filed Feb 7, 2018 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,014 | $82.48 | $83,634.72 |
DisclosureSEC source: 0001209191-18-008219 · doc4.xml · nonDerivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Former Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,946 F4 · kind: Payment of tax liability by withholding 1,014 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,636) maintained by the Reporting Person. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 9,250 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008219 · doc4.xml · derivative · entry 4 OBrien Christopher Flint · CIK 0001343124 · Former Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 9,250 shares Expires 2028-02-05 F5 · derivative.exercise_date: Represents option of which 1/24th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/24th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,113 | $83.40 | $92,819.41 |
DisclosureSEC source: 0001209191-18-008219 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Former Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,310 F3 · kind: Sale of 1,113 shares of common stock issued upon vesting of restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,500 | $83.01 | $124,522.05 |
DisclosureSEC source: 0001209191-18-008219 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Former Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,223 F1 · kind: Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 21:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,750 | $79.14 | $138,499.03 |
DisclosureSEC source: 0001209191-18-004246 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,723 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 16, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $76.09 to $82.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon Qualified Stock Option · Derivative | 7,518 | $8.65 Strike: $8.65 | $65,030.70 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · derivative · entry 7 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,823 Underlying: Common Stock · 7,518 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 14,049 | $8.66 Strike: $8.66 | $121,664.34 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · derivative · entry 6 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,049 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon Qualified Stock Option · Derivative | 31,250 | $8.66 Strike: $8.66 | $270,625.00 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · derivative · entry 5 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,049 Underlying: Common Stock · 31,250 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 7,518 | $69.71 | $524,046.70 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · nonDerivative · entry 4 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $68.21 to $71.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 7,518 | $8.65 | $65,030.70 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · nonDerivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 45,299 | $69.71 | $3,157,593.97 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $68.21 to $71.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 21:45 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 45,299 | $8.66 | $392,289.34 |
DisclosureSEC source: 0001209191-17-059434 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 23:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 6,925 | $8.65 Strike: $8.65 | $59,901.25 |
DisclosureSEC source: 0001209191-17-055457 · doc4.xml · derivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,341 Underlying: Common Stock · 6,925 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 10, 2013 and vested over 4 years. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 23:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 6,925 | $61.04 | $422,702.00 |
DisclosureSEC source: 0001209191-17-055457 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $60.40 to $61.93. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 23:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 6,925 | $8.65 | $59,901.25 |
DisclosureSEC source: 0001209191-17-055457 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 52,817 | $8.66 Strike: $8.66 | $457,395.22 |
DisclosureSEC source: 0001209191-17-051944 · doc4.xml · derivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,299 Underlying: Common Stock · 52,817 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted January 12, 2012 and vested in 36 equal monthly installments. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 52,817 | $57.50 | $3,036,977.50 |
DisclosureSEC source: 0001209191-17-051944 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $57.50 to $57.52. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:55 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 52,817 | $8.66 | $457,395.22 |
DisclosureSEC source: 0001209191-17-051944 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 8,734 | $8.65 Strike: $8.65 | $75,549.10 |
DisclosureSEC source: 0001209191-17-046685 · doc4.xml · derivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,266 Underlying: Common Stock · 8,734 shares Expires 2023-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted January 10, 2013 and vested over 4 years. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 8,734 | $50.00 | $436,700.00 |
DisclosureSEC source: 0001209191-17-046685 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 8,734 | $8.65 | $75,549.10 |
DisclosureSEC source: 0001209191-17-046685 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 21,884 | $8.66 Strike: $8.66 | $189,515.44 |
DisclosureSEC source: 0001209191-17-034638 · doc4.xml · derivative · entry 7 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,116 Underlying: Common Stock · 21,884 shares Expires 2022-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted January 12, 2012 and vests in 36 equal monthly installments. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 24,105 | $5.76 Strike: $5.76 | $138,844.80 |
DisclosureSEC source: 0001209191-17-034638 · doc4.xml · derivative · entry 6 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,105 shares Expires 2021-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 59,645 | $5.76 Strike: $5.76 | $343,555.20 |
DisclosureSEC source: 0001209191-17-034638 · doc4.xml · derivative · entry 5 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,105 Underlying: Common Stock · 59,645 shares Expires 2021-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 105,634 | $53.32 | $5,632,404.88 |
DisclosureSEC source: 0001209191-17-034638 · doc4.xml · nonDerivative · entry 4 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $52.27 to $53.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 21,884 | $8.66 | $189,515.44 |
DisclosureSEC source: 0001209191-17-034638 · doc4.xml · nonDerivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 24,105 | $5.76 | $138,844.80 |
DisclosureSEC source: 0001209191-17-034638 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 59,645 | $5.76 | $343,555.20 |
DisclosureSEC source: 0001209191-17-034638 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 20:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 204 | $51.23 | $10,450.92 |
DisclosureSEC source: 0001209191-17-026884 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,973 F1 · kind: Sale of 13,065 shares of common stock issued upon vesting of 25,000 performance restricted stock units on April 11, 2017 to cover withholding taxes, with the balance of the shares (11,935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $51.19 to $51.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 20:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 12,861 | $50.41 | $648,323.01 |
DisclosureSEC source: 0001209191-17-026884 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,177 F1 · kind: Sale of 13,065 shares of common stock issued upon vesting of 25,000 performance restricted stock units on April 11, 2017 to cover withholding taxes, with the balance of the shares (11,935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $50.20 to $50.73. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Option · Derivative | 10,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008912 · doc4.xml · derivative · entry 3 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 76,800 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008912 · doc4.xml · derivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,800 Underlying: Common Stock · 76,800 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,206 | $43.17 | $52,063.02 |
DisclosureSEC source: 0001209191-17-008912 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,038 F1 · kind: Sale of 1206 shares of common stock issued upon vesting of 3200 restricted stock units to cover withholding taxes with the balance of the shares (1994) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.91 to $43.46. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,500 | $42.50 | $63,750.00 |
DisclosureSEC source: 0001209191-17-008131 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,044 F1 · kind: Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 3, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $41.80 to $43.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:41 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,750 | $40.66 | $71,155.00 |
DisclosureSEC source: 0001209191-17-004301 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,544 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 17, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $39.91 to $41.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,750 | $43.35 | $75,862.50 |
DisclosureSEC source: 0001209191-17-003588 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,794 F1 · kind: Sale of 1,750 shares of common stock issued upon vesting of 3,500 restricted stock units on January 10, 2017 to cover payroll and withholding taxes, with the balance of the shares (1,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.50 to $45.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 20:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 25,000 | $52.84 | $1,321,000.00 |
DisclosureSEC source: 0001209191-16-150474 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,044 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $52.29 to $54.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.